CoChat

Matrix-bound nanovesicles alleviate particulate-induced periprosthetic osteolysis

Open access

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

Aseptic loosening of orthopedic implants is an inflammatory disease characterized by immune cell activation, chronic inflammation, and destruction of periprosthetic bone, and is one of the leading reasons for prosthetic failure, affecting 12% of total joint arthroplasty patients. Matrix-bound nanovesicles (MBVs) are a subclass of extracellular vesicle recently shown to mitigate inflammation in preclinical models of rheumatoid arthritis and influenza-mediated “cytokine storm.” The molecular mechanism of these anti-inflammatory properties is only partially understood. The objective of the present study was to investigate the effects of MBV on RANKL-induced osteoclast formation in vitro and particulate-induced osteolysis in vivo. Results showed that MBV attenuated osteoclast differentiation and activity by suppressing the NF-κB signaling pathway and downstream NFATc1, DC-STAMP, c-Src, and cathepsin K expression. In vivo, local administration of MBV attenuated ultrahigh molecular weight polyethylene particle-induced osteolysis, bone reconstruction, and periosteal inflammation. The results suggest that MBV may be a therapeutic option for preventing periprosthetic loosening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.adn1852

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. MBV characterization and assessment of cytocompatibility. (A) TEM imaging of MBV isolated from porcine urinary bladder matrix (UBM). Scale bar, 100 nm. (B) MBV size as measured by nanoparticle tracking analysis (NTA). (C) RAW264.7 cells were treated with phosphate-buffered saline (PBS), 5% dimethyl sulfoxide (DMSO), and serial dilutions of MBV ranging from 1.25 × 109 to 1 × 1010 particles/ml (MBV versus cells ratio 1.25 × 105 to 1 × 106 particles/ml per cell) for 24 hours and assayed for cytotoxicity by live/dead staining. Representative fluorescence images. Scale bars, 100 μm. (D) Percentage of live cells. PBS control, 5% DMSO, and various doses of MBV. Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (E) Cell proliferation and cytotoxicity were assessed by cell counting kit 8 (CCK-8) assay. Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. OD450, optical density at 450 nm.
Fig. 1. MBV characterization and assessment of cytocompatibility. (A) TEM imaging of MBV isolated from porcine urinary bladder matrix (UBM). Scale bar, 100 nm. (B) MBV size as measured by nanoparticle tracking analysis (NTA). (C) RAW264.7 cells were treated with phosphate-buffered saline (PBS), 5% dimethyl sulfoxide (DMSO), and serial dilutions of MBV ranging from 1.25 × 109 to 1 × 1010 particles/ml (MBV versus cells ratio 1.25 × 105 to 1 × 106 particles/ml per cell) for 24 hours and assayed for cytotoxicity by live/dead staining. Representative fluorescence images. Scale bars, 100 μm. (D) Percentage of live cells. PBS control, 5% DMSO, and various doses of MBV. Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (E) Cell proliferation and cytotoxicity were assessed by cell counting kit 8 (CCK-8) assay. Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. OD450, optical density at 450 nm.CC BY · PubMed Central
Fig. 2. MBVs mitigate RANKL-induced osteoclast formation and activity in vitro. (A) Cellular uptake of MBV by RAW 264.7 cells. CFSE-labeled (green) MBV were added to the RAW 264.7 cells culture media for 1 hour; nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI; blue), and cytoskeleton F-actin was labeled with 594-phalloidin (orange) before imaging. Representative IF images (40× and enlarged). Scale bars for 40× images, 50 μm; enlarged images, 10 μm. (B) MBVs reduce osteoclasts differentiation. RAW 264.7 cells were cultured with RANKL (30 ng/ml) and serial doses of MBV ranging from 0 to 5 × 109 MBV/ml for 5 days. Osteoclasts were determined with tartrate-resistant acid phosphatase (TRAP) staining. Representative light microscope TRAP staining images (10× and enlarged). Scale bars, 200 μm. (C) Raw 264.7 cells were cultured with RANKL (30 ng/ml) with or without MBV for 5 days. Actin ring formation was determined with FITC-phalloidin, and nuclei were labeled with DAPI. Representative immunofluorescence images (1× and 40×). Scale bars for 1× images, 2000 μm; 40× images, 100 μm. (D) MBVs reduce osteoclasts activity. RAW 264.7 cells were cultured with RANKL (30 ng/ml) and serial doses of MBV ranging from 0 to 5 × 109 MBV/ml on a calcium phosphate–coated plate for 7 days. Resorption areas were determined with a light microscope (5×). Scale bars, 500 μm. (E) Numbers of osteoclasts (TRAP positive, nuclei > 3). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (F) Average cell area (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (G) At day 6, bone resorption assay culture media were tested for fluorescence intensity. Fluorescence intensity (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (H) Resorption pit area (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05.
Fig. 2. MBVs mitigate RANKL-induced osteoclast formation and activity in vitro. (A) Cellular uptake of MBV by RAW 264.7 cells. CFSE-labeled (green) MBV were added to the RAW 264.7 cells culture media for 1 hour; nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI; blue), and cytoskeleton F-actin was labeled with 594-phalloidin (orange) before imaging. Representative IF images (40× and enlarged). Scale bars for 40× images, 50 μm; enlarged images, 10 μm. (B) MBVs reduce osteoclasts differentiation. RAW 264.7 cells were cultured with RANKL (30 ng/ml) and serial doses of MBV ranging from 0 to 5 × 109 MBV/ml for 5 days. Osteoclasts were determined with tartrate-resistant acid phosphatase (TRAP) staining. Representative light microscope TRAP staining images (10× and enlarged). Scale bars, 200 μm. (C) Raw 264.7 cells were cultured with RANKL (30 ng/ml) with or without MBV for 5 days. Actin ring formation was determined with FITC-phalloidin, and nuclei were labeled with DAPI. Representative immunofluorescence images (1× and 40×). Scale bars for 1× images, 2000 μm; 40× images, 100 μm. (D) MBVs reduce osteoclasts activity. RAW 264.7 cells were cultured with RANKL (30 ng/ml) and serial doses of MBV ranging from 0 to 5 × 109 MBV/ml on a calcium phosphate–coated plate for 7 days. Resorption areas were determined with a light microscope (5×). Scale bars, 500 μm. (E) Numbers of osteoclasts (TRAP positive, nuclei > 3). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (F) Average cell area (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (G) At day 6, bone resorption assay culture media were tested for fluorescence intensity. Fluorescence intensity (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05. (H) Resorption pit area (n = 4). Values are shown as mean ± SD (n = 4). Significant differences were determined as *P < 0.05.CC BY · PubMed Central
Fig. 3. MBVs mitigate RANKL-induced osteoclast formation and functions by suppressing NF-κB pathway in vitro. RAW 264.7 cells were challenged with RANKL and various concentrations of MBV (1× 1010 to 2× 1010 particles/ml, MBV versus cells ratio 1× 104 to 2 × 104 particles/ml per cell), 1 day for osteoclast differentiation and activity–related gene RT-qPCR (A and B; RANKL, 50 ng/ml), 3 days for osteoclast differentiation and activity–related protein Western blot (C; RANKL, 50 ng/ml), and 5 days for TNF-α concentration in conditional media (D; RANKL, 30 ng/ml; MBV, 5× 109 particles/ml). (A) Osteoclast differentiation regulators (NFATc1 and DC-STAMP) relative expression (2−△△T) were measured by RT-qPCR (values = means ± SD; n = 9; significant differences, *P < 0.05). (B) Osteoclast activity–related genes (cathepsinK, c-Src, MMP-9, and β3-integrin) relative expressions (2−△△T) were measured by RT-qPCR (values = means ± SD; n = 9; significant differences, *P < 0.05). (C) Osteoclast differentiation–related protein (NFATc1) and osteoclast activity proteins (c-Src and cathepsin K) relative expression was measured by Western blot (values = means ± SD; n = 3; significant differences, *P < 0.05). (D) TNF-α in conditional media from Raw 264.7 cells cocultured with RANKL with or without MBV for 5 days was determined by ELISA (values = means ± SD; n = 3; significant differences, *P < 0.05). (E) RAW 264.7 cells were challenged with RANKL (50 ng/ml) and MBV (2 × 1010 particles/ml) from 0 to 60 min. NF-κB pathway proteins were determined by Western blot. Representative Western blotting images of the effects of MBV on p-p65, p65, and IĸB-α. Quantification of the ratios of band intensity of p-p65/p65 and IĸBα relative to β-actin expression (values = means ± SD; n = 3; significant differences, *P < 0.05).
Fig. 3. MBVs mitigate RANKL-induced osteoclast formation and functions by suppressing NF-κB pathway in vitro. RAW 264.7 cells were challenged with RANKL and various concentrations of MBV (1× 1010 to 2× 1010 particles/ml, MBV versus cells ratio 1× 104 to 2 × 104 particles/ml per cell), 1 day for osteoclast differentiation and activity–related gene RT-qPCR (A and B; RANKL, 50 ng/ml), 3 days for osteoclast differentiation and activity–related protein Western blot (C; RANKL, 50 ng/ml), and 5 days for TNF-α concentration in conditional media (D; RANKL, 30 ng/ml; MBV, 5× 109 particles/ml). (A) Osteoclast differentiation regulators (NFATc1 and DC-STAMP) relative expression (2−△△T) were measured by RT-qPCR (values = means ± SD; n = 9; significant differences, *P < 0.05). (B) Osteoclast activity–related genes (cathepsinK, c-Src, MMP-9, and β3-integrin) relative expressions (2−△△T) were measured by RT-qPCR (values = means ± SD; n = 9; significant differences, *P < 0.05). (C) Osteoclast differentiation–related protein (NFATc1) and osteoclast activity proteins (c-Src and cathepsin K) relative expression was measured by Western blot (values = means ± SD; n = 3; significant differences, *P < 0.05). (D) TNF-α in conditional media from Raw 264.7 cells cocultured with RANKL with or without MBV for 5 days was determined by ELISA (values = means ± SD; n = 3; significant differences, *P < 0.05). (E) RAW 264.7 cells were challenged with RANKL (50 ng/ml) and MBV (2 × 1010 particles/ml) from 0 to 60 min. NF-κB pathway proteins were determined by Western blot. Representative Western blotting images of the effects of MBV on p-p65, p65, and IĸB-α. Quantification of the ratios of band intensity of p-p65/p65 and IĸBα relative to β-actin expression (values = means ± SD; n = 3; significant differences, *P < 0.05).CC BY · PubMed Central
Fig. 4. MBV biodistribution in mouse model of particulate-induced calvarial osteolysis. (A) Experiment design. Mice skull and periosteum were exposed to UHMWPE particles. Near-infrared (NIR)–labeled MBV pericalvarial administrated post-UHMWPE implantation surgery. From 0 hour to 7 days postsurgery, fluorescence signal was examined by an in vivo imagine system (IVIS). (B) Representative IVIS images from 0 hour to 7 days. (C) Seven days postinjection, mice were euthanized, and organs and bones were taken for IVIS imaging. Representative organs and bone IVIS images. (D) Total radiant efficacy ([p/s]/[uW/cm2]) of the calvarial region from 0 hour to 7 days (values = means ± SD; n = 5). (E) Total radiant efficacy ([p/s]/[uW/cm2]) of skull, liver, kidneys, and femur-tibia (values = means ± SD; n = 5; significant differences, *P < 0.05).
Fig. 4. MBV biodistribution in mouse model of particulate-induced calvarial osteolysis. (A) Experiment design. Mice skull and periosteum were exposed to UHMWPE particles. Near-infrared (NIR)–labeled MBV pericalvarial administrated post-UHMWPE implantation surgery. From 0 hour to 7 days postsurgery, fluorescence signal was examined by an in vivo imagine system (IVIS). (B) Representative IVIS images from 0 hour to 7 days. (C) Seven days postinjection, mice were euthanized, and organs and bones were taken for IVIS imaging. Representative organs and bone IVIS images. (D) Total radiant efficacy ([p/s]/[uW/cm2]) of the calvarial region from 0 hour to 7 days (values = means ± SD; n = 5). (E) Total radiant efficacy ([p/s]/[uW/cm2]) of skull, liver, kidneys, and femur-tibia (values = means ± SD; n = 5; significant differences, *P < 0.05).CC BY · PubMed Central
Fig. 5. Local administration of MBV alleviates osteolysis and bone remodeling in mouse model of UHMWPE particulate-induced osteolysis. (A) Experimental design and treatment regimen. (B) Mice were euthanized to harvest skull specimens at day 28. Representative morphology images of mice skull. Scale bars, 10 mm. (C) Representative images of mice skull dorsal/ventral micro-CT imaging 3D reconstruction. Scale bars, 2 mm. (D) Representative images of coronal cross section of micro-CT scan of mouse skull. Scale bars, 2 mm. (E) Quantification of cortical porosity (Ct.Po) and bone volume versus tissue volume (BV/TV) of skull. (values = means ± SD; n = 5; significant differences, *P < 0.05).
Fig. 5. Local administration of MBV alleviates osteolysis and bone remodeling in mouse model of UHMWPE particulate-induced osteolysis. (A) Experimental design and treatment regimen. (B) Mice were euthanized to harvest skull specimens at day 28. Representative morphology images of mice skull. Scale bars, 10 mm. (C) Representative images of mice skull dorsal/ventral micro-CT imaging 3D reconstruction. Scale bars, 2 mm. (D) Representative images of coronal cross section of micro-CT scan of mouse skull. Scale bars, 2 mm. (E) Quantification of cortical porosity (Ct.Po) and bone volume versus tissue volume (BV/TV) of skull. (values = means ± SD; n = 5; significant differences, *P < 0.05).CC BY · PubMed Central
Fig. 6. MBV alleviates inflammatory and osteoclastic activities in UHMWPE particulate-induced osteolysis. (A) Representative images of mice calvarial bone coronal paraffin sections (10× and 20×) hematoxylin and eosin (H&E) staining. Scale bars for 10× images, 500 μm; for 20× images, 200 μm. (B) Representative images of mice calvarial bone paraffin sections (20× and 40×) TRAP staining. Scale bars for 20× images, 200 μm; for 40× images, 100 μm. (C) Representative images of calvarial bone coronal paraffin sections (20× and 40×) TNF-α immunohistology [immunohistochemistry (IHC)] staining. Scale bars for 20× images, 100 μm; for 40× images, 50 μm. (D) Periosteal thickness of H&E staining images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05. (E) TRAP+ cells numbers per 20× images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05. (F) TNF-α cells percentage per 20× images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05.
Fig. 6. MBV alleviates inflammatory and osteoclastic activities in UHMWPE particulate-induced osteolysis. (A) Representative images of mice calvarial bone coronal paraffin sections (10× and 20×) hematoxylin and eosin (H&E) staining. Scale bars for 10× images, 500 μm; for 20× images, 200 μm. (B) Representative images of mice calvarial bone paraffin sections (20× and 40×) TRAP staining. Scale bars for 20× images, 200 μm; for 40× images, 100 μm. (C) Representative images of calvarial bone coronal paraffin sections (20× and 40×) TNF-α immunohistology [immunohistochemistry (IHC)] staining. Scale bars for 20× images, 100 μm; for 40× images, 50 μm. (D) Periosteal thickness of H&E staining images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05. (E) TRAP+ cells numbers per 20× images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05. (F) TNF-α cells percentage per 20× images. Values are shown as mean ± SD (n = 5); significant differences, *P < 0.05.CC BY · PubMed Central
Fig. 7. Schematic illustration of the mechanism by which MBVs reduce particulate-induced osteolysis. MBVs were derived from a porcine urinary bladder extracellular matrix (UBM) bioscaffold. In vitro, MBVs reduce monocyte/macrophage differentiation to osteoclast by suppressing the NF-κB pathway and its downstream NFATc1, DC-STAMP, c-Src, and cathepsin K expression. In vivo, MBVs alleviate UHMWPE particle-induced osteolysis in a murine calvarial osteolysis model.
Fig. 7. Schematic illustration of the mechanism by which MBVs reduce particulate-induced osteolysis. MBVs were derived from a porcine urinary bladder extracellular matrix (UBM) bioscaffold. In vitro, MBVs reduce monocyte/macrophage differentiation to osteoclast by suppressing the NF-κB pathway and its downstream NFATc1, DC-STAMP, c-Src, and cathepsin K expression. In vivo, MBVs alleviate UHMWPE particle-induced osteolysis in a murine calvarial osteolysis model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 59 references

Cited by

Metadata

Authors
Liao, R., Dewey, M. J., Rong, J., Johnson, S. A., D’Angelo, W. A., Hussey, G. S., & Badylak, S. F.
Affiliations
  • Central South University (CN)
  • University of Pittsburgh (US)
Corresponding author
Badylak, Stephen F.
Venue
Science Advances
Published
2024-10-18
Volume
10
Issue
42
Pages
eadn1852-eadn1852
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4403532962
Cited by
20
References
60
Citations by year
2026: 10 · 2025: 10
FWCI
8.38
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (TL1TR001858)
  • National Center for Research Resources (S10 RR016236)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Surgery › Orthopaedic implants and arthroplasty
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
periprosthetic osteolysis, aseptic loosening, extracellular vesicles, osteoclastogenesis, RANKL, NF-κB signaling, polyethylene wear particles, bone reconstruction, anti-inflammatory therapy, arthroplasty
MeSH terms
Extracellular Vesicles, RAW 264.7 Cells, Animals, Cell Differentiation, Disease Models, Animal, Extracellular Matrix, Osteoclasts, Osteogenesis, Osteolysis, Prosthesis Failure, Signal Transduction, NF-kappa B, Mice, RANK Ligand, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.